Abbott Raises 2026 Outlook After Solid Q2 Beat Driven by Diagnostics and Devices
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.
/ 7 items
#ABT↓
Edwards’ Ecliptis Wins FDA Clearance, Challenges AtriCure in Surgical LAA Market
Edwards got FDA OK for heart clip; it enters a market led by AtriCure, adding competition but not changing the outlook much.
Edwards Lifesciences Gets Big Boost as CMS Expands TAVR Coverage to Asymptomatic Patients
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
Abbott Beats Q1 Profit and Revenue Estimates, But Cuts 2026 Outlook After $23B Exact Sciences Deal
Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.
Abbott Laboratories Stock Plunges on Nutrition Division Struggles and Weak Guidance
Abbott (ABT) stock fell 8% after missing Q4 earnings expectations, with nutrition sales dropping 8.9% due to lower volumes and strategic price cuts on baby formula and supplements.
Abbott Makes Major Move in Cancer Diagnostics with $21B Exact Sciences Acquisition
Abbott to acquire Exact Sciences for $21 billion, gaining leadership in cancer screening with Cologuard and expanding its diagnostics portfolio into fast-growing oncology segment.